Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT02942407

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02942407
Other papers using this trial's data
  • Apixaban for Patients With Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial Circulation, 2022-12-06 DOI, PubMed 36335914

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02942407. Randomized; no masking; primary purpose treatment. Start 2016-12 (actual); primary completion 2019-07-27 (actual). Results posted on 2020-12-29.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate Anticoagulation Therapy in Hemodialysis Patients With Atrial Fibrillation
Acronym
RENAL-AF
Condition
End Stage Renal Disease
Intervention (Drug)
apixaban
Intervention (Drug)
warfarin
Lead sponsor
Christopher Granger, MD (class: other)
Collaborator
Bristol-Myers Squibb (class: industry)

Record details

Record id
cardio:ct-nct02942407
Content hash
a880027884e85cb74de564355d561188a5d2cefc2b2e5c277fdceecfdc1b566d